Cite
HARVARD Citation
Lickliter, J. et al. (n.d.). AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers. Annals of the rheumatic diseases. pp. 1413-1414. [Online].